Project Grant R21DA058110
Award Date
9/15/24
Completion Date
8/31/26
Dollars Obligated
$245K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) is intended to develop and evaluate the efficacy of a universal overdose prevention intervention to be delivered in primary care settings. The $2,467,574 award will fund a pilot two-arm cluster randomized controlled trial at Boston Medical Center to assess the acceptability and feasibility of the intervention for providers and youth ages 13-26. The...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $399,536 to Chemregen Inc.'s Human Biomolecular Research Institute in San Diego, CA. The funding supports research to design, synthesize, and test non-opioid drug candidates as potential treatments for opioid use disorder and fentanyl toxicity. Key objectives include characterizing the effects of opioids on human induced pluripotent stem...
This Project Grant award of $994,004, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to engage adolescents, young adults, parents, providers, pharmacists, and people who use drugs to generate knowledge to guide future overdose prevention interventions tailored for youth. The key objectives are to: 1) explore perceptions of overdose risk, drug supply, and safety precautions among 13-17 and 18-25 year olds through focus...
This federal Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $671,732 to The Washington University to conduct research on the mechanisms underlying fentanyl-induced cardiorespiratory depression. The goal is to evaluate the use of peripherally-acting mu opioid receptor (MOR) antagonists to prevent and reverse fentanyl overdoses without the aversive withdrawal effects seen with naloxone. The research also aims...
This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the NIH's Drug Use and Addiction Research Programs (CFDA 93.279), will fund a $751,043 research project at the University of Massachusetts Medical School focused on investigating the cellular and molecular mechanisms underlying the complex co-morbidity of opioid use disorder (OUD), major depressive disorder (MDD), and HIV in the human brain. The project will leverage single-cell sequencing technologies and other...
This federal Project Grant award, valued at $825,383, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant will fund research to investigate the role of molecular rhythms in the striatum on sleep and opioid use disorder (OUD). Key objectives include: Using single nuclei RNA-sequencing and time-of-death analyses to create a cell type-specific map of molecular rhythms in subregions of the human striatum. Comparing...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will provide $234,000.00 to Georgetown University to conduct research on the effect of opioids on HIV transcription and latency. The key objectives are to understand the mechanisms by which opioids such as fentanyl, morphine, and methadone influence HIV proviral transcription in microglia and astrocytes, as well as to longitudinally measure and...
This Project Grant award of $2,331,737 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a comprehensive study to investigate the impact of methamphetamine (MA) use on HIV persistence, immune dysfunction, and clinical outcomes among people living with HIV (PWH) on antiretroviral therapy (ART). The study will leverage three unique cohorts to perform the first-in-human investigations directly quantifying MA concentrations in...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $425,636 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct patient-oriented substance use and smoking cessation research in the context of HIV treatment and prevention. The key activities funded under this 5-year award include: 1) Mentoring junior researchers (pre- and post-doctoral fellows,...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $267,310 to the University of Miami to assess the functional role of calcitonin gene-related peptide (CGRP) expressing neurons within the parabrachial nucleus (CGRPPBN) in opioid reinforcement and to determine the associated gene expression and epigenetic changes. The goal is to explore non-opioid targets to treat opioid use disorder, a...